254 related articles for article (PubMed ID: 18391996)
1. A voice with no words.
Nat Biotechnol; 2008 Apr; 26(4):358. PubMed ID: 18391996
[No Abstract] [Full Text] [Related]
2. The best companies bare all.
Jacobs T
Nat Biotechnol; 2004 Nov; 22(11):1363. PubMed ID: 15529156
[No Abstract] [Full Text] [Related]
3. Maturing biotechs turn to pharma's markets.
Ratner M
Nat Biotechnol; 2005 Mar; 23(3):269. PubMed ID: 15765067
[No Abstract] [Full Text] [Related]
4. Assets for mastering media relations.
Steinerman P
Nat Biotechnol; 2003 Jul; 21 Suppl():BE59-61. PubMed ID: 12874984
[No Abstract] [Full Text] [Related]
5. Bio-Vision 2016: the second national framework plan for biotechnology promotion in Korea.
Hyeon BH; Kim HY; Lee CM; Moon SH; Kim ES; Lee SY
Biotechnol J; 2008 May; 3(5):591-600. PubMed ID: 18446865
[No Abstract] [Full Text] [Related]
6. Strategies in education and outreach.
Mills J
J Nucl Med; 2008 Jun; 49(6):73N-75N. PubMed ID: 18511836
[No Abstract] [Full Text] [Related]
7. Can China bring its own pipeline to the market?
Louët S
Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646
[No Abstract] [Full Text] [Related]
8. Counterpoint: biotech needs more than DTC as usual.
Mack J
Nat Biotechnol; 2006 Mar; 24(3):267. PubMed ID: 16525380
[No Abstract] [Full Text] [Related]
9. Point: Biotech needs direct to consumer communications.
Oestreicher P; Warner T
Nat Biotechnol; 2006 Mar; 24(3):265-6. PubMed ID: 16525378
[No Abstract] [Full Text] [Related]
10. Big biotech embraces direct-to-consumer advertising.
Katsnelson A
Nat Biotechnol; 2005 Oct; 23(10):1193. PubMed ID: 16211045
[No Abstract] [Full Text] [Related]
11. Perspective: Why communication in biotechnology is important.
Gassen HG
Biotechnol J; 2007 Sep; 2(9):1051-2. PubMed ID: 17768767
[No Abstract] [Full Text] [Related]
12. Marketing groups merge. Rx communications pros get national organization.
Robeznieks A
Mod Healthc; 2007 Jun; 37(25):17. PubMed ID: 17824503
[No Abstract] [Full Text] [Related]
13. The seven deadly sins of business development.
Stewart JJ; Bonifant B
Nat Biotechnol; 2008 Apr; 26(4):375-7. PubMed ID: 18404814
[No Abstract] [Full Text] [Related]
14. Making the case for molecular imaging.
Schick M
J Nucl Med; 2008 Jun; 49(6):75N-77N. PubMed ID: 18511837
[No Abstract] [Full Text] [Related]
15. Session 4: strategies for getting the word out.
Atcher R
J Nucl Med; 2008 Jun; 49(6):70N-71N. PubMed ID: 18511834
[No Abstract] [Full Text] [Related]
16. Challenges in realizing the potential of clinical molecular imaging.
Lusser M
J Nucl Med; 2008 Jun; 49(6):72N-73N. PubMed ID: 18511835
[No Abstract] [Full Text] [Related]
17. Giving the industry a face.
Siebert M
Med Device Technol; 2001 Dec; 12(10):36-7. PubMed ID: 15966145
[No Abstract] [Full Text] [Related]
18. To err is human, to correct divine: the emergence of technology-based communication systems.
Brenner RJ
J Am Coll Radiol; 2006 May; 3(5):340-5. PubMed ID: 17412078
[TBL] [Abstract][Full Text] [Related]
19. Leading biotechnology companies quit the IBA.
Gershon D
Nature; 1990 Apr; 344(6266):481. PubMed ID: 2320118
[No Abstract] [Full Text] [Related]
20. Hearts and minds.
Nat Biotechnol; 2007 Feb; 25(2):143. PubMed ID: 17287730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
